{
    "clinical_study": {
        "@rank": "99183", 
        "arm_group": [
            {
                "arm_group_label": "ACWY1d group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive 1 dose of the MenACWY-TT vaccine"
            }, 
            {
                "arm_group_label": "ACWY2d group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart"
            }, 
            {
                "arm_group_label": "Co-ad group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13\u2122"
            }, 
            {
                "arm_group_label": "PCV-13 group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive 1 dose of Prevenar 13\u2122 and 1 dose of the MenACWY-TT vaccine 2 months later"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the immunogenicity and safety of GSK Biologicals'\n      MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14\n      months. Also, this study will also assess if co-administration of GSK Biologicals'\n      MenACWY-TT with the booster dose of Pfizer's Prevenar 13 adversely impacts the\n      immunogenicity of either of the vaccines or not."
        }, 
        "brief_title": "Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13\u2122Vaccine", 
        "completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Meningococcal", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion\n             of the investigator, can and will comply with the requirements of the protocol.\n\n          -  A male or female between, and including, 12 and 14 months of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Vaccination records showing the completion of the full primary vaccination schedule\n             with Prevenar 13 and Diphtheria, Tetanus and Pertussis (DTP) containing vaccine\n             according to local recommendations at least 5 months before the study entry.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccines within 30 days preceding the first dose of study vaccine or planned\n             use during the study period.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within six months prior to the first vaccine dose.\n             For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled\n             and topical steroids are allowed.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             within the period starting 30 days before and ending 30 days after the dose of\n             vaccines, with the exception of a licensed inactivated influenza vaccine. Measles,\n             Mumps Rubella (MMR) vaccine or Measles Mumps Rubella and Varicella (MMRV) vaccine can\n             be co-administered with MenACWY-TT and/or Prevenar 13. A DTPa containing vaccine can\n             be administered after the last blood sampling (at Visit 2 or 4 depending on the\n             group).\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product (pharmaceutical product or device).\n\n          -  Previous vaccination against Neisseria meningitidis.\n\n          -  Previous booster vaccination against Streptococcus pneumoniae.\n\n          -  Previous booster vaccination against Corynebacterium diphtheriae, Clostridium tetani\n             and Bordetella pertussis.\n\n          -  History of meningococcal disease.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital\n             or secondary), including human immunodeficiency virus (HIV) infection, based on\n             medical history and physical examination.\n\n          -  Family history of congenital or hereditary immunodeficiency.\n\n          -  History of any reaction or hypersensitivity, including to diphtheria toxoid, likely\n             to be exacerbated by any component of the vaccines.\n\n          -  Major congenital defects or serious chronic illness.\n\n          -  History of any neurological disorders or seizures, including Guillain-Barr\u00e9 syndrome\n             (GBS). History of a simple, single febrile seizure is permitted.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the first dose of study vaccine or planned administration during the study\n             period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "14 Months", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939158", 
            "org_study_id": "116892", 
            "secondary_id": "2013-001083-28"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PCV-13 group", 
                    "ACWY2d group", 
                    "Co-ad group", 
                    "ACWY1d group"
                ], 
                "description": "1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region", 
                "intervention_name": "Meningococcal vaccine GSK134612", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "PCV-13 group", 
                    "Co-ad group"
                ], 
                "description": "1 dose administered intramuscularly in the right anterolateral thigh or deltoid region", 
                "intervention_name": "Prevenar 13\u2122", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Safety", 
            "Persistence", 
            "Immunogenicity", 
            "Prevenar 13", 
            "Meningococcal vaccine", 
            "Toddlers", 
            "5 years"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Garran", 
                        "country": "Australia", 
                        "state": "Australian Capital Territory", 
                        "zip": "2606"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2031"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "North Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5006"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Carlton", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3053"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Subiaco", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6008"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3A 1M3"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3K 6R8"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8L 5G8"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 1H5"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Qu\u00e9bec City", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1E 7G9"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Benesov", 
                        "country": "Czech Republic", 
                        "zip": "256 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Decin", 
                        "country": "Czech Republic", 
                        "zip": "405 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Domazlice", 
                        "country": "Czech Republic", 
                        "zip": "34401"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Jindrichuv Hradec", 
                        "country": "Czech Republic", 
                        "zip": "37701"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Kladno", 
                        "country": "Czech Republic", 
                        "zip": "272 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Liberec", 
                        "country": "Czech Republic"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Nachod", 
                        "country": "Czech Republic", 
                        "zip": "547 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Novy Jicin", 
                        "country": "Czech Republic", 
                        "zip": "741 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Odolena voda", 
                        "country": "Czech Republic", 
                        "zip": "25070"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Ostrava - Poruba", 
                        "country": "Czech Republic", 
                        "zip": "70800"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Ostrov", 
                        "country": "Czech Republic", 
                        "zip": "363 01"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Pardubice", 
                        "country": "Czech Republic", 
                        "zip": "532 03"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Praha 6", 
                        "country": "Czech Republic", 
                        "zip": "1600"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tabor", 
                        "country": "Czech Republic", 
                        "zip": "390 02"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Trutnov", 
                        "country": "Czech Republic"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "6100"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35100"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Canada", 
                "Czech Republic", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Immunogenicity and Safety Study of 1 and 2 Doses of GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Pneumococcal Vaccine Prevenar 13\u2122", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Biologics and Genetic Therapies Directorate (BGTD)", 
                "Turkey: T.R Ministry of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Australia: Therapeutics Goods Administration (TGA)"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8", 
                "measure": "Immunogenicity with respect to components of the study vaccines in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "1 month after administration of 1 dose of MenACWY-TT in the ACWY1d, ACWY2d and Co-ad groups and 2 doses in the ACWY2d group"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8, \u2265 1:128 and titres in the ACWY1d and ACWY2d groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "At Year 1"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8, \u2265 1:128 and titres in the ACWY1d and ACWY2d groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "At Year 3"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8, \u2265 1:128 and titres in the ACWY1d and ACWY2d groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "At Year 5"
            }, 
            {
                "description": "Anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations in the Co-ad and PCV-13 groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines in terms of antibody concentration", 
                "safety_issue": "No", 
                "time_frame": "1 month after administration of Prevenar 13"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939158"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titres \u2265 1:4, \u2265 1:8 and titres", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of hSBA titres", 
                "safety_issue": "No", 
                "time_frame": "1 month after administration of 1 dose of MenACWY-TT in a subset of subjects in the ACWY1d and ACWY2d groups and 2 doses in the ACWY2d group"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8, \u2265 1:128 and titres in the PCV-13 group", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "1 month after administration of 1 dose of MenACWY-TT"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:128 and titres in the ACWY1d, ACWY2d and Co-ad groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "1 month after administration of 1 dose of MenACWY-TT"
            }, 
            {
                "description": "Percentage of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titres \u2265 1:4, \u22651:8 and titres in a subset of subjects in the ACWY1d and ACWY2d groups.", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of hSBA titres", 
                "safety_issue": "No", 
                "time_frame": "At Years 1, 3 and 5"
            }, 
            {
                "description": "Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres \u2265 1:8, \u22651:128 and titres in the Co-ad and PCV-13 groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres", 
                "safety_issue": "No", 
                "time_frame": "At Years 1, 3 and 5"
            }, 
            {
                "description": "Percentage of subjects with anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations \u2265 0.15 \u00b5g/ml, \u2265 0.26 \u00b5g/ml and \u2265 0.35 \u00b5g/ml in the Co-ad and PCV-13 groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of antibody concentration", 
                "safety_issue": "No", 
                "time_frame": "One month after administration of Prevenar 13"
            }, 
            {
                "description": "Percentage of subjects with anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F OPA titres \u2265 1:8 and titres in the Co-ad and PCV-13 groups", 
                "measure": "Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of OPA titres", 
                "safety_issue": "No", 
                "time_frame": "One month after administration of Prevenar 13"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 4 days (Day 0 - Day 3) after each study vaccination"
            }, 
            {
                "description": "Occurrence of unsolicited AEs according to the Medical Dictionary for Regulatory Activities (MedDRA) classification", 
                "measure": "Occurrence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "Within 31 days (Day 0 - Day 30) after any study vaccination"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "From Month 0 to Month 9"
            }, 
            {
                "description": "Occurrence of SAEs related to study vaccine administration and any event related to lack of vaccine efficacy (i.e. meningococcal disease)", 
                "measure": "Occurrence of SAEs related to study vaccine administration", 
                "safety_issue": "No", 
                "time_frame": "From the first receipt of study vaccine until study end (Year 5)"
            }, 
            {
                "description": "E.g. asthma, autoimmune disorders, type 1 diabetes, allergies", 
                "measure": "Occurrence of New Onset Chronic Illnesses (NOCIs)", 
                "safety_issue": "No", 
                "time_frame": "From Month 0 to Month 9"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}